Copeptin as a Prognostic Marker in Acute Chest Pain and Suspected Acute Coronary Syndrome

Table 1

Baseline characteristics in patients positive and negative for copeptin.

	Overall cohort; ()	Copeptin < 17.4 pmol/l; ()	Copeptin ≥ 17.4 pmol/l; ()	value
Baseline parameters and medical history
Age (years)	63 (57–73)	62 (56–69)	65 (57–78)	0.04
Male sex	100, 65%	72, 65.5%	28, 58.3%	0.25
BMI (kg/m^2)	28.7 (42.9–32.3)	28 (25–32)	29 (25–32)	0.93
CAD	67, 44%	50, 45.5%	17, 35.4%	0.17
Hypertension	114, 74%	75, 68.2%	39, 81.3%	0.17
Diabetes mellitus	42, 27%	28, 25.5%	14, 29.2%	0.72
PAD	4, 2.6%	3, 2.7%	1, 2.1%	0.79
Familial history of CAD	21, 14%	18, 16.4%	3, 6.3%	0.07
Current smoker	51, 33%	38, 34.5%	13, 27.1%	0.28
Past smoker	31, 20%	23, 20.9%	8, 16.7%	0.47
Dyslipidemia	67,44%	49, 44.5%	18, 37.5%	0.31
History of AMI	46, 30%	36, 32.7%	10, 20.8%	0.10
History of PCI	48, 31%	36, 32.7%	12, 25.0%	0.27
History of CABG	7, 4.5%	7, 6.4%	0, 0%	0.07
History of stroke	4, 2.6%	3, 2.7%	1, 2.1%	0.79
Baseline clinical status
Heart rate (beats/min)	75 (66–88)	70 (65–80)	75 (70–85)	0.07
Systolic BP	140 (123–160)	140 (125–160)	140 (120–160)	0.54
EF (%)	55 (45–60)	55 (45–60)	55 (43–60)	0.56
NYHA class III or IV	4, 2.6%	1, 0.9%	3, 6.3%	0.06
Killip class				0.50
1	139, 90%	98, 89.1%	41, 85.4%
2	14, 9.1%	7, 6.4%	7, 14.6%
3	1, 0.6%	1, 0.9%	0, 0%
4	0, 0%	0, 0%	0, 0%
GRACE	124 (104–146)	120 (101–141)	131 (111–167)	0.03
Laboratory parameters
Hs-TnT T0 (ng/l)	33 (13–143)	25 (11–125)	68 (30–177)	0.01
Hs-TnT T6 (ng/l)	75 (16–397)	32 (13–247)	234 (43–2284)	<0.001
Hs-TnT max (ng/l)	105 (23–530)	52 (17–274)	236 (74–2070)	<0.001
CK-MB T0 (IU/l)	20 (15–30)	19 (14–28)	22 (17–36)	0.06
CK-MB T6 (IU/l)	21 (14–45)	18 (13–32)	33 (18–107)	<0.001
CK-MB max (IU/l)	27 (18–53)	25 (17–42)	42 (25–111)	<0.001
NT-proBNP (pg/ml)	350 (163–1074)	289 (150–872)	491 (223–1979)	0.02
CRP (mg/l)	2.9 (1.3–5.5)	3 (1–5)	4 (2–7)	0.03
Leukocytosis (10^3/μl)	8.4 (6.9–10.3)	8 (6–9)	10 (8–12)	<0.001
Hemoglobin (g/dl)	14 (13–15)	14 (13–15)	14 (13–15)	0.34
GFR (ml/min/1.73m^2)	92 (76–110)	93 (77–115)	90 (67–99)	0.08
In-hospital parameters
Diagnosis of CAD	116, 75%	83, 75.5%	33, 68.8%	0.11
Medical therapy	38, 25%	25, 22.7%	13, 27.1%	0.64
PCI	90, 58%	60, 54.5%	30, 62.5%	0.49
CABG	33, 21%	25, 22.7%	8, 16.7%	0.33
Catecholamines	4, 2.6%	0, 0%	4, 8.3%	0.003
ASA	141, 92%	97, 88.2%	44, 91.7%	0.79
DAPT	99, 64%	68, 61.8%	31, 64.6%	0.96
β-Blocker	134, 87%	93, 84.5%	41, 85.4%	0.81
ACE inhibitor	126, 82%	91, 82.7%	35, 72.9%	0.07
Statin	135, 88%	95, 86.4%	40, 83.3%	0.26
Diuretic	45, 29%	31, 28.2%	14, 29.2%	0.97
Ca-blocker	39, 25%	27, 24.5%	12, 25.0%	0.98
Nitroglycerin	17, 11%	12, 10.9%	5, 10.4%	0.89
Final diagnosis
Unstable angina	30, 20%	27, 24.5%	3, 6.3%	0.005
NSTEMI	105, 68%	65, 59.1%	40, 83.3%	0.007

Data presented as n, %, or median (25th–75th interquartile range). ACE: angiotensin-converting enzyme; AMI: acute myocardial infarction; ASA: acetylsalicylic acid; BMI: body mass index; BP: blood pressure; CABG: coronary artery bypass grafting; CAD: coronary artery disease; CK-MB: creatine kinase myocardial bound; CRP: C-reactive protein; DAPT: dual antiplatelet treatment; EF: ejection fraction; GFR: glomerular filtration ratio; GRACE: Global Registry for Acute Coronary Events; Hs-TnT: high-sensitive troponin T; NSTEMI: non-ST segment elevation myocardial infarction; NT-proBNP: N-terminal pro-B-type natriuretic peptide; NYHA: New York Heart Association; PAD: peripheral artery disease; PCI: percutaneous coronary intervention.